Dawnrays Pharmaceutical (Holdings) Ltd is an investment holding company mainly engaged in the development, manufacture and sale of non-patented drugs. The Company operates its business through two segments. The finished drugs segment is engaged in the manufacture and sale of finished drugs. The intermediates and bulk medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines.

Employees

1,081

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-23	HK$1.000	0.00%	4,000
26-07-22	HK$1.000	0.00%	0
26-07-21	HK$1.000	0.00%	36,000
26-07-20	HK$1.000	0.00%	0
26-07-17	HK$1.000	0.00%	50,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. Other stock markets 04:08:06 2026-07-23 EDT			5-day change	1st Jan Change
1.000 ^HKD	0.00%		0.00%	-18.03%

05-29	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg	CI
05-22	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025	CI

Market Cap	1.3B 1.51B 192M 169M 157M 144M 270M 18.56B 276M 1.87B 730M 9.07B 722M 706M 31.49B	P/E 2024	3.06x	P/E 2025	7.83x
Enterprise Value	-427M -494M -63.04M -55.3M -51.36M -47.23M -88.6M -6.09B -90.49M -614M -239M -2.97B -237M -232M -10.33B	EV / Sales 2024	0.14x	EV / Sales 2025	-0.06x
Free-Float	32.59%	Yield 2024	5.16%	Yield 2025	5.16%

05-29	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg	CI
05-22	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025	CI
03-27	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-27	Dawnrays Pharmaceutical (Holdings) final dividend of HK$0.048 per share	RE
03-27	Dawnrays Pharmaceutical Limited Proposes Final Cash Dividend for the Year Ended December 31, 2025, Payable on June 12, 2026	CI
25-08-22	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-22	Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2025, Payable on 03 October 2025	CI
25-08-22	Dawnrays pharmaceutical reports HY net income attributable of RMB104.6 mln	RE
25-07-31	Dawnrays Pharmaceutical Limited Announces Appointment of Hu Shuo as Non-Executive Director with Effect from 1 August 2025	CI
25-05-23	Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended 31 December 2024	CI
25-05-23	Dawnrays Pharmaceutical Limited Declares Special Dividend for the Year Ended 31 December 2024	CI
25-03-28	Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million	RE
25-03-28	Dawnrays Pharmaceutical Limited Proposes Special Dividend for the Year Ended December 31, 2024, Payable on 12 June 2025	CI

21-04-19	Dawnrays Pharmaceutical : Form of proxy for use at the Annual General Meeting of the Company to be held on Friday, 28 May 2021 (or at any adjournment thereof)	PU
21-04-19	Dawnrays Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	PU
20-09-23	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
20-09-22	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
20-09-21	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU

Dawnrays Pharmaceutical (Holdings) Limited Stock

Stocks

2348

KYG2687M1006

Pharmaceuticals

Valuation: Dawnrays Pharmaceutical (Holdings) Limited

Chart: Dawnrays Pharmaceutical (Holdings) Limited

Latest news : Dawnrays Pharmaceutical (Holdings) Limited

Press Releases: Dawnrays Pharmaceutical (Holdings) Limited

Quotes and Performance

Course Extremes

Managers and Directors: Dawnrays Pharmaceutical (Holdings) Limited

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Current month	-1.96%
1 month	-3.85%
3 months	-12.28%
6 months	-14.53%
Current year	-18.03%

1 week	1	1
1 month	0.98	1.03
Current year	0.98	1.22
1 year	0.98	1.45
3 years	0.98	1.47
5 years	0.98	1.82
10 years	0.84	2.88

Manager	Title	Age	Since
Li Wei Yu CEO	Chief Executive Officer	56	2024-09-12
Yi jun Wu DFI	Director of Finance/CFO	61	-
Michelle Li IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Kei Ling Li CHM	Chairman	77	2002-09-30
Yung Lai Hung BRD	Director/Board Member	81	2002-09-30
Hong Man Leung BRD	Director/Board Member	51	2005-10-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/25/26	Fortune United Group Ltd	Other	Company	72,000	0.0048%
6/25/26	Kei Ling Li	Other	Chairman	72,000	0.0048%
5/14/26	Kei Ling Li	Other	Chairman	36,000	0.0024%

	2024	2025
Net sales	1.06B 1.23B 157M 137M 128M 117M 220M 15.13B 225M 1.53B 595M 7.39B 588M 576M 25.67B	1.23B 1.43B 182M 160M 148M 136M 256M 17.56B 261M 1.77B 691M 8.58B 683M 668M 29.8B
Net income	565M 655M 83.49M 73.23M 68.01M 62.55M 117M 8.06B 120M 813M 317M 3.94B 313M 307M 13.68B	214M 248M 31.62M 27.74M 25.76M 23.69M 44.44M 3.05B 45.39M 308M 120M 1.49B 119M 116M 5.18B
Net Debt	-1.57B -1.82B -232M -204M -189M -174M -327M -22.45B -334M -2.26B -883M -10.97B -873M -854M -38.08B	-1.73B -2B -255M -224M -208M -191M -359M -24.65B -366M -2.49B -969M -12.04B -958M -938M -41.81B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED	0.00%	0.00%	-24.81%	-18.70%	192M
ELI LILLY AND COMPANY	+1.97%	+2.53%	+52.73%	+156.66%	1,037B
JOHNSON & JOHNSON	+1.42%	+4.96%	+54.39%	+52.34%	615B
ABBVIE INC.	+1.43%	+5.25%	+37.31%	+78.74%	448B
ROCHE HOLDING AG	+5.14%	+5.84%	+37.54%	+27.28%	326B
NOVARTIS AG	+1.85%	+4.64%	+38.53%	+39.87%	293B
ASTRAZENECA PLC	-0.11%	+0.97%	+22.57%	+17.81%	264B
NOVO NORDISK A/S	+0.25%	-3.10%	-24.44%	-42.25%	216B
AMGEN INC.	+1.49%	+3.68%	+21.53%	+58.21%	198B
GILEAD SCIENCES, INC.	+0.40%	-0.64%	+18.78%	+62.28%	162B
Average	+0.70%	+1.01%	+23.41%	+43.22%	355.76B
Weighted average by Cap.	+0.43%	+1.47%	+38.32%	+75.23%